Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series

Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series

Abstract Background Monoclonal antibodies targeting the PD-1/PD-L1 axis have gained increasing attention across many solid tumors and hematologic malignancies due to their efficacy and favorable toxicity profile. With more than 1 agent now FDA-approved in a wide variety of tumor types, and with othe...

Full description

Bibliographic Details
Main Authors: Dylan J. Martini, Aly-Khan A. Lalani, Dominick Bossé, John A. Steinharter, Lauren C. Harshman, F. Stephen Hodi, Patrick A. Ott, Toni K. Choueiri
Format: Article
Language:English
Published: BMJ Publishing Group 2017-08-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
PD-1/PD-L1 inhibitor
Sequential treatment
Immune checkpoint blockade
Case reports
Online Access:http://link.springer.com/article/10.1186/s40425-017-0273-y

Internet

http://link.springer.com/article/10.1186/s40425-017-0273-y

Similar Items